Naloxone reverses opioid overdose but must be re-dosed more frequently than many long-acting opioids. The pharmacokinetic reason for this mismatch is:

• A Naloxone is metabolised by CYP3A4 to a toxic metabolite that competitively displaces it from μ-opioid receptors
• B Naloxone's oral bioavailability is near zero, so it cannot be converted to an extended-release form for ambulatory use
• C Naloxone binds μ-opioid receptors covalently, preventing re-administration within 4 hours
• D Naloxone is rapidly glucuronidated with a half-life of ~60–90 minutes; long-acting opioids like methadone have half-lives of 24–36 hours, so repeated naloxone doses or infusion are needed ✓

Explanation

Naloxone has a very short half-life of approximately 60–90 minutes due to rapid hepatic first-pass glucuronidation (forming naloxone-3-glucuronide). Many opioids have longer half-lives: methadone 24–36 hours, extended-release opioids 12–24 hours, fentanyl in overdose can accumulate in fat. As naloxone is cleared while the opioid persists, the patient can re-narcotise — particularly dangerous with methadone or fentanyl overdose. Clinical management requires repeated naloxone boluses, or an IV infusion (~2/3 of the effective reversal dose per hour), and extended observation (4–12 hours minimum for long-acting opioids). Naloxegol and methylnaltrexone are peripherally restricted analogues used for opioid-induced constipation.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.